METUCHEN, NJ – (BUSINESS WIRE) – January 12, 2022–

Tevogen Bio, a clinical-stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11 219,684) for the specific preparation method of COVID-19 peptide cytotoxic T cells (CTL) for the treatment of COVID-19 infection. Patent further strengthens biotechnology pioneer’s expanding intellectual property wallet.

“Omicron’s extensive mutations and its subsequent ability to evade antibodies highlight the importance of Killer T cells, which can still recognize and kill cells infected with the virus,” said the CEO of Tevogen. Ryan saadi, MD, MPH “Millions of us suffer from an inadequate T cell response for a variety of reasons. After two years of a pandemic and witnessing the challenges posed by the constantly evolving virus, we must explore scientific options beyond our current approaches. CTL therapy for large patient populations is no easy undertaking, but Tevogen’s ability to manufacture hundreds of doses from a single donor gives me hope, ”Saadi added.

The granted patent covers the experimental allogeneic therapy of Tevogen’s SARS-CoV-2 specific cytotoxic CD8 + T lymphocytes (CTLs), TVGN-489, for high-risk COVID-19 patients. The product is currently undergoing a proof of concept clinical test at Jefferson University Hospitals in Philadelphia. Details of the trial are available at Clinical trials – Tevogen.

TVGN-489 is a highly purified, cytotoxic CD8 + T lymphocyte product specific for SARS-CoV-2, which detects targets distributed throughout the viral genome. These targeted CTLs should recognize and kill cells infected with a virus, allowing the body to replace them with healthy, uninfected cells. TVGN-489 demonstrated strong antiviral activity against SARS-CoV-2 targets in preclinical studies.

Tevogen Bio is led by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and marketed several franchises. Tevogen management believes that accessible personalized immunotherapies are the next frontier in medicine and that disruptive business models are needed to support medical innovation in the post-pandemic world.

Forward-looking statements

This press release contains certain forward-looking statements relating to the development by Tevogen Bio ™ Inc. (the “Company”) and patient access to its innovations in infectious disease and oncology. These statements are based on the current expectations and beliefs of management as of the date of this press release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors beyond the control of company that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied in these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief about future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be. hit. These factors include the results of ongoing or ongoing clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing, and FDA / EMA actions. The Company assumes no obligation to update any forward-looking statements or information contained in this press release, or to provide additional information, and expressly disclaims all liability and makes no representations or warranties in connection herewith or with respect to concerns any omission thereof.

Head of corporate communications



Copyright Business Wire 2022.

PUB: 12/01/2022 19:45 / DISC: 12/01/2022 19:47

Copyright Business Wire 2022.


Bakersfield doctor publicly reprimanded by state medical board for keeping records


Hot-Shooting Gents breaks record for three scorers in one match in victory over Southwest

Check Also